Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction

Article Cardiac & Cardiovascular Systems

Splanchnic Nerve Block Mediated Changes in Stressed Blood Volume in Heart Failure

Marat Fudim et al.

Summary: The study analyzed data from two prospective clinical studies on decompensated HFrEF and ambulatory heart failure patients. The results showed that splanchnic nerve block decreased the estimated stressed blood volume in decompensated HFrEF patients, while it increased in ambulatory HFrEF patients.

JACC-HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first-in-human clinical trial

Filip Malek et al.

Summary: This study showed that GSN ablation in patients with HFpEF is feasible and resulted in reduced cardiac filling pressure during exercise, improved quality of life, and exercise capacity.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Review Cardiac & Cardiovascular Systems

Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations

Marat Fudim et al.

Summary: Volume recruitment from the splanchnic compartment is a crucial physiological response to stressors such as physical activity and blood loss. Excess fluid redistribution from this compartment in heart failure patients can lead to increased cardiac filling pressures and reduced exercise capacity. Blocking neural activity of the greater splanchnic nerve may provide significant benefits in some heart failure patients, but the long-term safety of splanchnic nerve modulation therapy remains unknown.

EUROPEAN JOURNAL OF HEART FAILURE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Theresa A. McDonagh et al.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker et al.

Summary: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems